Meisam Naeimi Kararoudi

Dr. Meisam Naeimi Kararoudi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Cell Reports Methods
Verified
Journal Article
Open access
MKMeisam Naeimi Kararoudi
Meisam Naeimi Kararoudi
SLShibi Likhite
Shibi Likhite
EEEzgi Elmas
Ezgi Elmas
KYKenta Yamamoto
Kenta Yamamoto
MSMaura Schwartz
Maura Schwartz
DLDean Lee
Dean Lee
Human primary natural killer (NK) cells are being widely advanced for cancer immunotherapy. However, methods for gene editing of these cells have suffered low transduction rates, high cell death, and loss of transgene expression after expansion. Here, we developed a highly efficient method for site-specific gene insertion in NK cells using CRISPR (Cas9/RNP) and AAVs. We compared AAV vectors designed to mediate gene insertion by different DNA repair mechanisms, homology arm lengths, and virus concentrations. We then validated the method for site-directed gene insertion of CD33-specific CARs into primary human NK cells. CAR transduction was efficient, its expression remained stable after expansion, and it improved efficacy against AML targets.

11 December 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
FHFaqrul Hasan
Faqrul Hasan
ACAmanda R Campbell
Amanda R Campbell
TCTayler J Croom-Perez
Tayler J Croom-Perez
JOJeremiah L Oyer
Jeremiah L Oyer
TDThomas A Dieffenthaller
Thomas A Dieffenthaller
ACAlicja J Copik
Alicja J Copik
Background: Inhibitory receptor T-cell Immunoreceptor with Ig and ITIM domains (TIGIT) expressed by Natural Killer (NK) and T cells regulates cancer immunity and has been touted as the next frontier in the development of cancer immunotherapeutics. Although early results of anti-TIGIT and its combinations with antiprogrammed death-ligand 1 were highly exciting, results from an interim analysis of phase III trials are disappointing. With mixed results, there is a need to understand the effects of therapeutic anti-TIGIT on the TIGIT+ immune cells to support its clinical use. Most of the TIGIT antibodies in development have an Fc-active domain, which binds to Fc receptors on effector cells. In mouse models, Fc-active anti-TIGIT induced superior immunity, while Fc receptor engagement was required for its efficacy. NK-cell depletion compromised the antitumor immunity of anti-TIGIT indicating the essential role of NK cells in the efficacy of anti-TIGIT. Since NK cells express TIGIT and Fc-receptor CD16, Fc-active anti-TIGIT may deplete NK cells via fratricide, which has not been studied. Methods: CRISPR-Cas9-based TIGIT knockout (KO) was performed in expanded NK cells. Phenotypic and transcriptomic properties of TIGIT KO and wild-type (WT) NK cells were compared with flow cytometry, CyTOF, and RNA sequencing. The effect of TIGIT KO on NK-cell cytotoxicity was determined by calcein-AM release and live cell imaging-based cytotoxicity assays. The metabolic properties of TIGIT KO and WT NK cells were compared with a Seahorse analyzer. The effect of the Fc-component of anti-TIGIT on NK-cell fratricide was determined by co-culturing WT and TIGIT KO NK cells with Fc-active and Fc-inactive anti-TIGIT. Results: TIGIT KO increased the cytotoxicity of NK cells against multiple cancer cell lines including spheroids. TIGIT KO NK cells upregulated mTOR complex 1 (mTORC1) signaling and had better metabolic fitness with an increased basal glycolytic rate when co-cultured with cancer cells compared with WT NK cells. Importantly, TIGIT KO prevented NK-cell fratricide when combined with Fc-active anti-TIGIT. Conclusions: TIGIT KO in ex vivo expanded NK cells increased their cytotoxicity and metabolic fitness and prevented NK-cell fratricide when combined with Fc-active anti-TIGIT antibodies. These fratricide-resistant TIGIT KO NK cells have therapeutic potential alone or in combination with Fc-active anti-TIGIT antibodies to enhance their efficacy.

5 April 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
EEEzgi Elmas
Ezgi Elmas
NSNoushin Saljoughian
Noushin Saljoughian
MPMarcelo de Souza Fernandes Pereira
Marcelo de Souza Fernandes Pereira
BTBrian P. Tullius
Brian P. Tullius
KSKinnari Sorathia
Kinnari Sorathia
MKMeisam Naeimi Kararoudi
Meisam Naeimi Kararoudi
Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat cancers. Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing has become one of the most popular tools to enhance immune cell antitumor activity. In this review we highlight applications and practicability of CRISPR/Cas9 gene editing and engineering strategies for cancer immunotherapy. In addition, we have reviewed several approaches to study CRISPR off-target effects.

5 September 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MKMeisam Naeimi Kararoudi
Meisam Naeimi Kararoudi
SHSeyyed S Hejazi
Seyyed S Hejazi
EEEzgi Elmas
Ezgi Elmas
MHMats Hellström
Mats Hellström
MKMaryam Naeimi Kararoudi
Maryam Naeimi Kararoudi
HDHamid Dolatshad
Hamid Dolatshad
Genetically modified pigs have been considered favorable resources in xenotransplantation. Microinjection of randomly integrating transgenes into zygotes, somatic cell nuclear transfer, homologous recombination, zinc finger nucleases, transcription activator-like effector nucleases, and most recently, clustered regularly interspaced short palindromic repeats-cas9 (CRISPR/Cas9) are the techniques that have been used to generate these animals. Here, we provide an overview of the CRISPR approaches that have been used to modify genes which are vital in improving xenograft survival rate, including cytidine monophosphate-N-acetylneuraminic acid hydroxylase, B1,4N-acetylgalactosaminyltransferase, isoglobotrihexosylceramide synthase, class I MHC, von Willebrand factor, C3, and porcine endogenous retroviruses. In addition, we will mention the importance of potential candidate genes which could be targeted using CRISPR/Cas9.

31 July 2024 in Blood Neoplasia
Verified
Journal Article
Open access
ETElla Troy
Ella Troy
JCJoseph Caporale
Joseph Caporale
YSYasemin Sezgin
Yasemin Sezgin
MPMarcelo S. F. Pereira
Marcelo S. F. Pereira
GBGregory K Behbehani
Gregory K Behbehani
MKMeisam Naeimi Kararoudi
Meisam Naeimi Kararoudi
• CD38-CAR NK and T cells showed enhanced killing toward CD38-expressing hematologic malignancies. • ATRA upregulates CD38, enhancing the activity of CD38-CAR NK cells against resistant CD38-low tumor cells.

10 May 2025 in Cytotherapy
Verified
Journal Article
Open access
JCJoseph R. Caporale
Joseph R. Caporale
MKMeisam Naeimi Kararoudi
Meisam Naeimi Kararoudi
MLMargaret G. Lamb
Margaret G. Lamb
DLDean Lee
Dean Lee
Natural killer (NK) cell therapy began decades ago with administration of small doses of minimally-characterized cells known as cytokine-induced or lymphokine-activated killer cells (CIK or LAK, respectively). Methods and conditions that enabled the broad adoption of T cell therapies have often been less effective for NK cells, but in the last 15 years, new NK-specific advances in selection, differentiation, and ex vivo expansion hav e made possible the infusion of large doses of pure and potent NK cell products. Also, NK cells have been more resistant to the genetic modification approaches utilized for engineering T cells, but in the last 5 years several robust approaches for NK cell modification have advanced to the clinic. Thus, a tremendous surge in NK cell clinical trials has been seen recently. Here, we present a focused perspective on the key developments in NK cell therapy that differentiate it from T cell therapies and discuss areas that are key to their clinical and commercial success- both current advancements and hurdles that remain to be addressed.